SCHEMBL6079703

SCHEMBL6079703

COC(=O)c1cc(O)c2cccc(C#N)c2n1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.40
GAA P10253 2/20 0.39
LCK P06239 1/20 0.39
KDM4E B2RXH2 4/20 0.39
MAPT P10636 3/20 0.39
HPGD P15428 2/20 0.39
LMNA P02545 2/20 0.39
PTGER4 P35408 1/20 0.39
TP53 P04637 1/20 0.39
MAPK1 P28482 1/20 0.39
HSD17B10 Q99714 1/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
RXFP1 Q9HBX9 1/20 0.38
CA12 O43570 1/20 0.38
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
CA7 P43166 1/20 0.38
CA9 Q16790 1/20 0.38
CA14 Q9ULX7 1/20 0.38
CRHBP P24387 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31726174 1.00 ALDH1A1 (0.40) ALDH1A1GAALCKKDM4EMAPT
SCHEMBL31726661 0.86 MAPT (0.41) ALDH1A1GAAKDM4EMAPTHPGD
SCHEMBL6079541 0.84 ALDH1A1 (0.40) ALDH1A1KDM4EHPGDLMNAHSD17B10
SCHEMBL1401121 0.84 GABRP (0.37) ALDH1A1GAALCKKDM4EMAPT
SCHEMBL6080470 0.83 KDM4E (0.43) KDM4EMAPTCA1CA2TDP1
SCHEMBL1401134 0.81 MAPT (0.45) ALDH1A1GAALCKKDM4EMAPT
SCHEMBL6080128 0.81 GAA (0.39) ALDH1A1GAALCKKDM4EMAPT
SCHEMBL1815489 0.80 MAPT (0.45) ALDH1A1GAALCKKDM4EMAPT
SCHEMBL561666 0.80 PDE10A (0.47) ALDH1A1GAALCKKDM4EMAPT
SCHEMBL2222961 0.80 ADORA2A (0.47) ALDH1A1GAALCKKDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060183909-A1 Compositions derived from quinoline and quinoxaline, preparation and use thereof NEURO3D (FR) 2006-08-17 US claimed
US-20060183909-A1 Compositions derived from quinoline and quinoxaline, preparation and use thereof NEURO3D (FR) 2006-08-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060183909-A1 Compositions derived from quinoline and quinoxaline, preparation and use thereof NQO1, NQO2, RECQL ALDH1A1 2726/4885GAA 589/4885LCK 1565/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.